Table 3.

Challenge results of the eliciting-dose from double-blind, placebo-controlled challenge (DBPCC) with rMal d 1 over time.

	DBPCC with rMal d 1
	Negative or Positive with Eliciting-Dose Reaction
Months	Before Start AIT	Dose Reaction	After 12 Months AIT	Dose Reaction	After 24 Months AIT	Dose Reaction
Patient
1	Pos	20 µg	Neg		Neg
2	Neg		Neg		Neg
3	Pos	50 µg	Pos	5 µg	Pos	5 µg
4	Neg		Pos	10 µg	UD
5	Pos	20 µg	Neg		Neg
6	Neg		Neg		Neg
7	Pos	10 µg	Neg		Neg
8	Neg		Pos	5 µg	Neg

DBPCC = double-blind, placebo-controlled oral challenge, AIT = allergen immunotherapy, Pos = a positive DBPCC with rMal d 1, Neg = a negative DBPCC with rMal d 1, UD = undecided. Doses of rMal d 1: dose 1 = 0 µg, dose 2 = 5 µg, dose 3 = 10 µg, dose 4 = 20 µg and dose 5 = 50 µg.